Systemic and transcardiac platelet activity in acute myocardial infarction in man: Resistance to prostacyclin

H. S. Mueller, P. S. Rao, Mark A. Greenberg, P. M. Buttrick, I. I. Sussman, H. A. Levite, R. M. Grose, V. Perez-Davila, J. E. Strain, T. H. Spaet

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

There is increasing evidence that platelets play an important role in the pathogenesis of acute ischemic heart disease. Therefore an understanding of factors that influence platelet performance is important. This study was undertaken (1) to characterize during evolving myocardial infarction platelet activity in the peripheral circulation and across the ischemic/infarcting myocardial compartment, the locus of presumed platelet hyperactivity, and (2) to evaluate the effects of prostacyclin (PGI2), a most potent antiplatelet agent and vasodilator. A total of 59 patients with evolving myocardial infarction were studied. Twenty-two patients were instrumented with arterial and coronary sinus catheters and received intravenous infusion of PGI2, 13 ± 4.5 ng/kg/min (mean ± SD), for 90 min. In 15 patients with anterior myocardial infarction, transcardiac platelet function and response to PGI2 were studied. Plasma levels of β-thromboglobulin (β-TG) and of thromboxane B2 (TxB2), in vivo measures of platelet activity, were elevated three- and 10-fold. 6-Keto-prostaglandin F(1α), the stable end product of PGI2, was less than 10 pg/ml, reflecting a leftward shift of the TxB2/PGI2 ratio. Platelets circulating during evolving myocardial infarction ('ischemic platelets') were hyperaggregable in response to ADP and relatively resistant to PGI2, both in vivo and in vitro. Concentrations of platelet cyclic AMP and the cyclic AMP response to PGI2 were diminished. The platelet hyperreactivity, expressed by plasma β-TG, platelet aggregation, and PGI2-induced inhibition of aggregation, was most intense early during infarct evolution and decreased with time. The increased platelet performance resulted in 'platelet fatigue', indicated by decreased contents of β-TG of the ischemic platelet and decreased TxA2 production in response to collagen. However, the ischemic platelet produced twice normal TxA2 in response to arachidonic acid (stimulus and substrate), demonstrating a heightened metabolic capacity. TxA2 was produced across the ischemic/infarcting compartment in 10 of 15 patients with anterior myocardial infarction. The antiplatelet effect of PGI2 was greatly diminished. In summary, the data define an abnormal pattern of platelet behavior during evolving myocardial infarction, characterized by a proaggregatory environment, heightened platelet reactivity in both the peripheral and coronary circulation, and relative resistance to PGI2. The clinical consequences of the data are that the patient in the acute phase of myocardial infarction may benefit from suspension of platelet function and requires significantly greater doses of PGI2 than normal subjects. The data also suggest future directions for therapeutic manipulation of platelet hyperreactivity in the setting of acute myocardial ischemia.

Original languageEnglish (US)
Pages (from-to)1336-1345
Number of pages10
JournalCirculation
Volume72
Issue number6
StatePublished - 1985

Fingerprint

Epoprostenol
Blood Platelets
Myocardial Infarction
Thromboxane B2
Cyclic AMP
Myocardial Ischemia
Coronary Circulation
Coronary Sinus
Platelet Aggregation Inhibitors
Prostaglandins F
Vasodilator Agents
Platelet Aggregation
Intravenous Infusions
Arachidonic Acid

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Mueller, H. S., Rao, P. S., Greenberg, M. A., Buttrick, P. M., Sussman, I. I., Levite, H. A., ... Spaet, T. H. (1985). Systemic and transcardiac platelet activity in acute myocardial infarction in man: Resistance to prostacyclin. Circulation, 72(6), 1336-1345.

Systemic and transcardiac platelet activity in acute myocardial infarction in man : Resistance to prostacyclin. / Mueller, H. S.; Rao, P. S.; Greenberg, Mark A.; Buttrick, P. M.; Sussman, I. I.; Levite, H. A.; Grose, R. M.; Perez-Davila, V.; Strain, J. E.; Spaet, T. H.

In: Circulation, Vol. 72, No. 6, 1985, p. 1336-1345.

Research output: Contribution to journalArticle

Mueller, HS, Rao, PS, Greenberg, MA, Buttrick, PM, Sussman, II, Levite, HA, Grose, RM, Perez-Davila, V, Strain, JE & Spaet, TH 1985, 'Systemic and transcardiac platelet activity in acute myocardial infarction in man: Resistance to prostacyclin', Circulation, vol. 72, no. 6, pp. 1336-1345.
Mueller, H. S. ; Rao, P. S. ; Greenberg, Mark A. ; Buttrick, P. M. ; Sussman, I. I. ; Levite, H. A. ; Grose, R. M. ; Perez-Davila, V. ; Strain, J. E. ; Spaet, T. H. / Systemic and transcardiac platelet activity in acute myocardial infarction in man : Resistance to prostacyclin. In: Circulation. 1985 ; Vol. 72, No. 6. pp. 1336-1345.
@article{969eaf001c4048d1a5c54465ea021722,
title = "Systemic and transcardiac platelet activity in acute myocardial infarction in man: Resistance to prostacyclin",
abstract = "There is increasing evidence that platelets play an important role in the pathogenesis of acute ischemic heart disease. Therefore an understanding of factors that influence platelet performance is important. This study was undertaken (1) to characterize during evolving myocardial infarction platelet activity in the peripheral circulation and across the ischemic/infarcting myocardial compartment, the locus of presumed platelet hyperactivity, and (2) to evaluate the effects of prostacyclin (PGI2), a most potent antiplatelet agent and vasodilator. A total of 59 patients with evolving myocardial infarction were studied. Twenty-two patients were instrumented with arterial and coronary sinus catheters and received intravenous infusion of PGI2, 13 ± 4.5 ng/kg/min (mean ± SD), for 90 min. In 15 patients with anterior myocardial infarction, transcardiac platelet function and response to PGI2 were studied. Plasma levels of β-thromboglobulin (β-TG) and of thromboxane B2 (TxB2), in vivo measures of platelet activity, were elevated three- and 10-fold. 6-Keto-prostaglandin F(1α), the stable end product of PGI2, was less than 10 pg/ml, reflecting a leftward shift of the TxB2/PGI2 ratio. Platelets circulating during evolving myocardial infarction ('ischemic platelets') were hyperaggregable in response to ADP and relatively resistant to PGI2, both in vivo and in vitro. Concentrations of platelet cyclic AMP and the cyclic AMP response to PGI2 were diminished. The platelet hyperreactivity, expressed by plasma β-TG, platelet aggregation, and PGI2-induced inhibition of aggregation, was most intense early during infarct evolution and decreased with time. The increased platelet performance resulted in 'platelet fatigue', indicated by decreased contents of β-TG of the ischemic platelet and decreased TxA2 production in response to collagen. However, the ischemic platelet produced twice normal TxA2 in response to arachidonic acid (stimulus and substrate), demonstrating a heightened metabolic capacity. TxA2 was produced across the ischemic/infarcting compartment in 10 of 15 patients with anterior myocardial infarction. The antiplatelet effect of PGI2 was greatly diminished. In summary, the data define an abnormal pattern of platelet behavior during evolving myocardial infarction, characterized by a proaggregatory environment, heightened platelet reactivity in both the peripheral and coronary circulation, and relative resistance to PGI2. The clinical consequences of the data are that the patient in the acute phase of myocardial infarction may benefit from suspension of platelet function and requires significantly greater doses of PGI2 than normal subjects. The data also suggest future directions for therapeutic manipulation of platelet hyperreactivity in the setting of acute myocardial ischemia.",
author = "Mueller, {H. S.} and Rao, {P. S.} and Greenberg, {Mark A.} and Buttrick, {P. M.} and Sussman, {I. I.} and Levite, {H. A.} and Grose, {R. M.} and V. Perez-Davila and Strain, {J. E.} and Spaet, {T. H.}",
year = "1985",
language = "English (US)",
volume = "72",
pages = "1336--1345",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Systemic and transcardiac platelet activity in acute myocardial infarction in man

T2 - Resistance to prostacyclin

AU - Mueller, H. S.

AU - Rao, P. S.

AU - Greenberg, Mark A.

AU - Buttrick, P. M.

AU - Sussman, I. I.

AU - Levite, H. A.

AU - Grose, R. M.

AU - Perez-Davila, V.

AU - Strain, J. E.

AU - Spaet, T. H.

PY - 1985

Y1 - 1985

N2 - There is increasing evidence that platelets play an important role in the pathogenesis of acute ischemic heart disease. Therefore an understanding of factors that influence platelet performance is important. This study was undertaken (1) to characterize during evolving myocardial infarction platelet activity in the peripheral circulation and across the ischemic/infarcting myocardial compartment, the locus of presumed platelet hyperactivity, and (2) to evaluate the effects of prostacyclin (PGI2), a most potent antiplatelet agent and vasodilator. A total of 59 patients with evolving myocardial infarction were studied. Twenty-two patients were instrumented with arterial and coronary sinus catheters and received intravenous infusion of PGI2, 13 ± 4.5 ng/kg/min (mean ± SD), for 90 min. In 15 patients with anterior myocardial infarction, transcardiac platelet function and response to PGI2 were studied. Plasma levels of β-thromboglobulin (β-TG) and of thromboxane B2 (TxB2), in vivo measures of platelet activity, were elevated three- and 10-fold. 6-Keto-prostaglandin F(1α), the stable end product of PGI2, was less than 10 pg/ml, reflecting a leftward shift of the TxB2/PGI2 ratio. Platelets circulating during evolving myocardial infarction ('ischemic platelets') were hyperaggregable in response to ADP and relatively resistant to PGI2, both in vivo and in vitro. Concentrations of platelet cyclic AMP and the cyclic AMP response to PGI2 were diminished. The platelet hyperreactivity, expressed by plasma β-TG, platelet aggregation, and PGI2-induced inhibition of aggregation, was most intense early during infarct evolution and decreased with time. The increased platelet performance resulted in 'platelet fatigue', indicated by decreased contents of β-TG of the ischemic platelet and decreased TxA2 production in response to collagen. However, the ischemic platelet produced twice normal TxA2 in response to arachidonic acid (stimulus and substrate), demonstrating a heightened metabolic capacity. TxA2 was produced across the ischemic/infarcting compartment in 10 of 15 patients with anterior myocardial infarction. The antiplatelet effect of PGI2 was greatly diminished. In summary, the data define an abnormal pattern of platelet behavior during evolving myocardial infarction, characterized by a proaggregatory environment, heightened platelet reactivity in both the peripheral and coronary circulation, and relative resistance to PGI2. The clinical consequences of the data are that the patient in the acute phase of myocardial infarction may benefit from suspension of platelet function and requires significantly greater doses of PGI2 than normal subjects. The data also suggest future directions for therapeutic manipulation of platelet hyperreactivity in the setting of acute myocardial ischemia.

AB - There is increasing evidence that platelets play an important role in the pathogenesis of acute ischemic heart disease. Therefore an understanding of factors that influence platelet performance is important. This study was undertaken (1) to characterize during evolving myocardial infarction platelet activity in the peripheral circulation and across the ischemic/infarcting myocardial compartment, the locus of presumed platelet hyperactivity, and (2) to evaluate the effects of prostacyclin (PGI2), a most potent antiplatelet agent and vasodilator. A total of 59 patients with evolving myocardial infarction were studied. Twenty-two patients were instrumented with arterial and coronary sinus catheters and received intravenous infusion of PGI2, 13 ± 4.5 ng/kg/min (mean ± SD), for 90 min. In 15 patients with anterior myocardial infarction, transcardiac platelet function and response to PGI2 were studied. Plasma levels of β-thromboglobulin (β-TG) and of thromboxane B2 (TxB2), in vivo measures of platelet activity, were elevated three- and 10-fold. 6-Keto-prostaglandin F(1α), the stable end product of PGI2, was less than 10 pg/ml, reflecting a leftward shift of the TxB2/PGI2 ratio. Platelets circulating during evolving myocardial infarction ('ischemic platelets') were hyperaggregable in response to ADP and relatively resistant to PGI2, both in vivo and in vitro. Concentrations of platelet cyclic AMP and the cyclic AMP response to PGI2 were diminished. The platelet hyperreactivity, expressed by plasma β-TG, platelet aggregation, and PGI2-induced inhibition of aggregation, was most intense early during infarct evolution and decreased with time. The increased platelet performance resulted in 'platelet fatigue', indicated by decreased contents of β-TG of the ischemic platelet and decreased TxA2 production in response to collagen. However, the ischemic platelet produced twice normal TxA2 in response to arachidonic acid (stimulus and substrate), demonstrating a heightened metabolic capacity. TxA2 was produced across the ischemic/infarcting compartment in 10 of 15 patients with anterior myocardial infarction. The antiplatelet effect of PGI2 was greatly diminished. In summary, the data define an abnormal pattern of platelet behavior during evolving myocardial infarction, characterized by a proaggregatory environment, heightened platelet reactivity in both the peripheral and coronary circulation, and relative resistance to PGI2. The clinical consequences of the data are that the patient in the acute phase of myocardial infarction may benefit from suspension of platelet function and requires significantly greater doses of PGI2 than normal subjects. The data also suggest future directions for therapeutic manipulation of platelet hyperreactivity in the setting of acute myocardial ischemia.

UR - http://www.scopus.com/inward/record.url?scp=0022373371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022373371&partnerID=8YFLogxK

M3 - Article

C2 - 2933181

AN - SCOPUS:0022373371

VL - 72

SP - 1336

EP - 1345

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6

ER -